BAIN CAPITAL LIFE SCIENCES INVESTORS LLC
Q1 2023 Form 13-F

BOSTON, MASSACHUSETTS
CIK 0001703031 · Institutional investment manager
Consolidated report · includes 14 managers since Q1 2021
$800.1M Reported Value Total
Reported value
$800.1M
Quarter over quarter
-7.6%
Holdings
34
Top-10 concentration
66.9%

Reports holdings for

  • Bain Capital Life Sciences Opportunities IV, L.P. (not a 13F filer in our records) · File #028-26575 · since Q1 2026 · declared by one filing
  • Bain Capital Life Sciences Opportunities IV GP, LLC (not a 13F filer in our records) · File #028-26576 · since Q1 2026 · declared by one filing
  • Bain Capital Life Sciences Fund IV, L.P. (not a 13F filer in our records) · File #028-26577 · since Q1 2026 · declared by one filing
  • Bain Capital Life Sciences IV General Partner, LLC (not a 13F filer in our records) · File #028-26578 · since Q1 2026 · declared by one filing
  • Bain Capital Life Sciences Fund II, L.P. (not a 13F filer in our records) · File #28-20814 · since Q1 2021 · declared by one filing
  • Bain Capital Life Sciences Investors II, LLC (not a 13F filer in our records) · File #28-20816 · since Q1 2021 · declared by one filing
  • Bain Capital Life Sciences Opportunities III, LP (not a 13F filer in our records) · File #28-22966 · since Q1 2023 · declared by one filing
  • Bain Capital Life Sciences Opportunities III GP, LLC (not a 13F filer in our records) · File #28-22968 · since Q1 2023 · declared by one filing
  • Bain Capital Life Sciences III General Partner, LLC (not a 13F filer in our records) · File #28-22975 · since Q1 2023 · declared by one filing
  • BCLS II Investco (GP), LLC (not a 13F filer in our records) · File #28-22976 · since Q1 2023 · declared by one filing
  • BCLS II Investco, LP (not a 13F filer in our records) · File #28-22978 · since Q1 2023 · declared by one filing
  • Bain Capital Life Sciences Fund III, L.P. (not a 13F filer in our records) · File #28-22979 · since Q1 2023 · declared by one filing
  • BCLS Fund III Investments GP, LLC (not a 13F filer in our records) · File #28-25138 · since Q1 2025 · declared by one filing
  • BCLS Fund III Investments, LP (not a 13F filer in our records) · File #28-25140 · since Q1 2025 · declared by one filing
  • Bain Capital Life Sciences Fund IV, L.P. (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
  • Bain Capital Life Sciences IV General Partner, LLC (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
  • Bain Capital Life Sciences Opportunities IV GP, LLC (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
  • Bain Capital Life Sciences Opportunities IV, L.P. (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
  • Bain Capital Life Sciences Partners, LP (not a 13F filer in our records) · File #28-18476 · Q1 2018 – Q3 2025 · declared by one filing
  • Bain Capital Life Sciences Fund, L.P. (not a 13F filer in our records) · File #28-18478 · Q1 2018 – Q3 2025 · declared by one filing
  • BCLS Fund III Investments GP, LLC (not a 13F filer in our records) · Q4 2024 – Q4 2024 · declared by one filing
  • BCLS Fund III Investments, LP (not a 13F filer in our records) · Q4 2024 – Q4 2024 · declared by one filing
  • BC SW, LP (not a 13F filer in our records) · File #28-20270 · Q2 2020 – Q3 2024 · declared by one filing
  • Bain Capital Life Sciences Fund III, L.P. (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
  • Bain Capital Life Sciences III General Partner, LLC (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
  • Bain Capital Life Sciences Opportunities III GP, LLC (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
  • Bain Capital Life Sciences Opportunities III, LP (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
  • BCLS II Investco (GP), LLC (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
  • BCLS II Investco, LP (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
  • BCIP Life Sciences Associates, LP (not a 13F filer in our records) · File #28-21927 · Q1 2022 – Q3 2022 · declared by one filing
  • BCIP Life Sciences Associates, LP (not a 13F filer in our records) · Q4 2021 – Q4 2021 · declared by one filing
  • Bain Capital Life Sciences Fund II, L.P. (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
  • Bain Capital Life Sciences Investors II, LLC (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
  • Bain Capital Life Sciences Partners, LP (not a 13F filer in our records) · File #028-18476 · Q1 2020 – Q1 2020 · declared by one filing
  • BC SW, LP (not a 13F filer in our records) · Q1 2020 – Q1 2020 · declared by one filing
  • Bain Capital Life Sciences Fund, L.P. (not a 13F filer in our records) · Q4 2017 – Q4 2017 · declared by one filing
  • Bain Capital Life Sciences Partners, LP (not a 13F filer in our records) · Q4 2017 – Q4 2017 · declared by one filing

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Adam Koppel
Partner of Bain Capital Life Sciences Investors, LLC
Q4 2022
Q2 2023
Go to latest
Loading 13F Metrics

Q1 2023 13F filing summary

Period of report March 31, 2023
Filed May 15, 2023
Form 13F-HR
Reported value $800.1M
Positions 34
Change in reported value -10.6%
New positions 3
Exited positions 2
Position turnover 13.9%
Top-10 concentration 66.9%

13F filings by quarter

Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
 21 $1.7B
Q1 2026 13F
Filed May 15, 2026
 20 $1.1B
Q4 2025 13F
Filed Feb 17, 2026
 19 $1.3B
Q3 2025 13F
Filed Nov 14, 2025
 21 $1.5B
Q2 2025 13F
Filed Aug 14, 2025
 23 $799.3M
Q1 2025 13F
Filed May 15, 2025
 24 $675.9M
Q4 2024 13F
Filed Feb 14, 2025
 26 $850.1M
Q3 2024 13F
Filed Nov 14, 2024
 24 $961.2M
Q2 2024 13F
Filed Aug 12, 2024
 25 $910.8M
Q1 2024 13F
Filed May 15, 2024
 26 $1.2B
Q4 2023 13F
Filed Feb 13, 2024
 27 $1.0B
Q3 2023 13F
Filed Nov 14, 2023
 31 $894.2M
Q2 2023 13F
Filed Aug 14, 2023
 32 $971.0M
Q1 2023 13F
Filed May 15, 2023
 34 $800.1M
Q4 2022 13F
Filed Feb 14, 2023
 33 $894.8M
Q3 2022 13F
Filed Nov 14, 2022
 33 $837.8M
Q2 2022 13F
Filed Aug 15, 2022
 35 $852.7M
Q1 2022 13F
Filed May 16, 2022
 34 $1.0B
Q4 2021 13F
Filed Feb 14, 2022
 34 $1.3B
Q3 2021 13F
Filed Nov 15, 2021
 33 $1.6B

15 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2023

# Holding Reported value % of portfolio
1 NAMS NEWAMSTERDAM PHARMA COMPANY $110.1M 13.76%
2 NUVL NUVALENT INC $93.3M 11.66%
3 SWTX SPRINGWORKS THERAPEUTICS INC $79.3M 9.91%
4 IRON DISC MEDICINE INC $42.2M 5.27%
5 NTRA NATERA INC $38.9M 4.86%
6 DVAX DYNAVAX TECHNOLOGIES CORP $38.4M 4.8%
7 CRNX CRINETICS PHARMACEUTICALS IN $37.0M 4.63%
8 MRSN MERSANA THERAPEUTICS INC $35.6M 4.45%
9 ARQT ARCUTIS BIOTHERAPEUTICS INC $33.0M 4.12%
10 ACRS ACLARIS THERAPEUTICS INC $27.5M 3.44%
11 PHVS PHARVARIS N V $25.6M 3.2%
12 SVRA SAVARA INC $22.7M 2.83%
13 CBAY CYMABAY THERAPEUTICS INC $21.8M 2.72%
14 CTIC CTI BIOPHARMA CORP $19.8M 2.47%
15 EQRX EQRX INC $19.4M 2.43%
16 ANNX ANNEXON INC $18.8M 2.35%
17 NRIX NURIX THERAPEUTICS INC $16.2M 2.02%
18 SLDB SOLID BIOSCIENCES INC $14.8M 1.85%
19 TSVT 2SEVENTY BIO INC $14.4M 1.8%
20 RPID RAPID MICRO BIOSYSTEMS INC $11.0M 1.38%

Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.

Loading Activities
Loading Sector Allocation
Crunching numbers
Loading Performance
Finding Potential New Buys
Building table
Loading SEC filing data
Loading Form 4 Filings
Loading 13D/G filings